iSpecimen (NASDAQ:ISPC) Shares Down 4.6% – Should You Sell?

iSpecimen Inc. (NASDAQ:ISPC) shares were down 4.6% during mid-day trading on Wednesday . The stock traded as low as $2.26 and last traded at $2.29. Approximately 40,362 shares traded hands during trading, a decline of 42% from the average session volume of 70,025 shares. The stock had previously closed at $2.40.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ISPC. Weiss Ratings reissued a “sell (e+)” rating on shares of iSpecimen in a report on Tuesday, April 21st. Wall Street Zen raised shares of iSpecimen to a “sell” rating in a research note on Saturday, May 2nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, iSpecimen currently has an average rating of “Sell”.

iSpecimen Price Performance

The firm has a market capitalization of $3.48 million, a PE ratio of -0.03 and a beta of 1.63. The business has a 50-day simple moving average of $3.39 and a 200-day simple moving average of $7.90.

iSpecimen (NASDAQ:ISPC) last announced its earnings results on Friday, May 15th. The company reported ($6.66) EPS for the quarter. The company had revenue of $0.16 million during the quarter. iSpecimen had a negative return on equity of 584.65% and a negative net margin of 1,080.16%.

Institutional Investors Weigh In On iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Virtu Financial LLC bought a new position in iSpecimen Inc. (NASDAQ:ISPC) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned about 0.65% of iSpecimen at the end of the most recent quarter. Institutional investors own 13.62% of the company’s stock.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.